Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Ascending Dose Study of SCO-240 in Healthy Adult Males
jRCT2051240252Phase 1Completed
- Sponsor
- SCOHIA PHARMA, Inc.
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SCO-240 in growth hormone deficiency (GHD) (5 arms), sponsored by SCOHIA PHARMA, Inc. Primary endpoints: Safety and tolerability of SCO-240 and Pharmacokinetics of SCO-240. Started Jan 2025; status: completed.
02
Drugs
SCO-240
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on jRCT2051240252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240252.